Cell-specific activation of gemcitabine by endogenous H2S stimulation and tracking through simultaneous fluorescence turn-on

Mrinmoy Maiti; Shin A Yoon; Yujin Cha; K K Athul; Sankarprasad Bhuniya; Min Hee Lee

doi:10.1039/d1cc00118c

Cell-specific activation of gemcitabine by endogenous H₂S stimulation and tracking through simultaneous fluorescence turn-on

Chem Commun (Camb). 2021 Sep 21;57(75):9614-9617. doi: 10.1039/d1cc00118c.

Authors

Mrinmoy Maiti¹, Shin A Yoon², Yujin Cha², K K Athul³, Sankarprasad Bhuniya³, Min Hee Lee²

Affiliations

¹ Department of Science, School of Engineering, Amrita Vishwa Vidyapeetham, Coimbatore, 641112, India.
² Department of Chemistry, Sookmyung Women's University, Seoul 04310, Korea. minheelee@sookmyung.ac.kr.
³ Centre for Interdisciplinary Science, JIS Institute of Advanced Studies and Research, JIS University, Salt Lake, Kolkata, 700091, India. spbhuniya@jisiasr.org.

PMID: 34486009
DOI: 10.1039/d1cc00118c

Abstract

The endogenous H₂S-driven theranostic H2S-Gem has been invented. The theranostic prodrug H2S-Gem is selectively activated in cancer cells, releasing active gemcitabine with a simultaneous fluorescence turn-on. H2S-Gem selectively inhibited cancer cell growth compared to the mother chemotherapeutic gemcitabine. Overall, it is a unique protocol for tracking and transporting chemotherapeutic agents to tumor areas without the guidance of tumor-directive ligands.

MeSH terms

Antimetabolites, Antineoplastic / chemistry
Antimetabolites, Antineoplastic / pharmacology*
Cell Proliferation / drug effects
Deoxycytidine / analogs & derivatives*
Deoxycytidine / chemistry
Deoxycytidine / pharmacology
Drug Screening Assays, Antitumor
Fluorescence
Gemcitabine
HeLa Cells
Humans
Hydrogen Sulfide / chemistry
Hydrogen Sulfide / pharmacology*
Ligands
Prodrugs / chemistry
Prodrugs / pharmacology*
Theranostic Nanomedicine

Substances

Antimetabolites, Antineoplastic
Ligands
Prodrugs
Deoxycytidine
Hydrogen Sulfide
Gemcitabine